Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP5541 versus abiraterone acetate in advanced metastatic prostate cancer
jRCT2031250142Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Aug 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of abiraterone decanoate in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa) (5 cohorts), sponsored by Astellas Pharma. Primary endpoints: PSA90 response in ARPI-naive mCRPC (Cohort 1), Mineralocorticoid toxicity-free rate in Cohort 2 safety run-in and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
abiraterone decanoate
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2031250142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250142.